Wave Life Sciences

Wave Life Sciences is a biotechnology company focused on developing RNA medicines. The company describes its goal as unlocking the broad potential of RNA medicines to transform human health. Its stated scientific approach combines a toolkit of RNA-targeting modalities, chemistry innovation, and insights from human genetics, with the aim of addressing both rare and common disorders. This positions Wave as a research-led drug developer rather than a consumer-facing healthcare provider or a seller of established medicines. The company’s work is organized around science and platform capabilities, research and development, clinical programs, collaborations, and manufacturing. Its website also provides information for patients and families, investors, employees, and potential partners. These functions indicate an organization engaged in drug discovery and development, clinical research, and the operational work needed to advance medicines, while the supplied materials do not establish that any particular product is approved or commercially marketed. One named program in the supplied company news is WVE-007, described as a GalNAc-siRNA and associated with INHBE. The homepage lists announcements about its clinical development, including the initiation of the Phase 2a portion of the INLIGHT trial and a planned Phase 2a combination trial with tirzepatide for obesity. These announcements describe investigational development activity; they should not be read as evidence of approval or availability as a treatment. Wave’s corporate headquarters is in Cambridge, Massachusetts. The company’s contact page also lists entities and offices in the United States, Singapore, Japan, the United Kingdom, and Ireland. Its leadership page names Paul Bolno as president and chief executive officer and identifies executives responsible for technology, science, medical affairs, finance, business development, strategy, human resources, legal affairs, translational medicine, and chemistry, manufacturing, and controls. The supplied sources do not identify a founder, founding year, parent company, or owner. Wave presents corporate responsibility, diversity, equity and inclusion, human capital, patient and community engagement, and environmental stewardship as areas of company-wide attention, with oversight of sustainability initiatives assigned to its Nominating & Corporate Governance Committee. Its website lists a September 2026 announcement of completion of a redomiciliation to Delaware. The available evidence does not establish the company’s listed status or ticker, so those are left unspecified here.

Wave Life Sciences is described in the supplied reference material as a biotechnology company. Its corporate identity centers on the development of RNA medicines: the company says it seeks to unlock the potential of RNA medicines to transform human health, drawing on RNA-targeting modalities, chemistry innovation, and human-genetics insights. The company states that this approach is intended to produce scientific advances for both rare and common disorders. The supplied sources do not give a founding date, founder, or account of the company’s origins, so no such details are assigned here. The company’s public-facing structure covers science, its PRISM platform, publications, collaborations, manufacturing, research and development, clinical programs, and a pipeline. This describes a drug-development organization with research and clinical-development activities, rather than a portfolio of documented marketed medicines in the evidence provided. The material does not establish that any named program has regulatory approval. Wave’s headquarters is listed at 733 Concord Avenue in Cambridge, Massachusetts. Its contact page also lists Wave Life Sciences USA, Inc. in Lexington, Massachusetts, Wave Life Sciences Ltd. in Singapore, Wave Life Sciences Japan, Inc. in Kagoshima, Wave Life Sciences UK Limited in Birmingham, and Wave Life Sciences Ireland Limited in Dublin. These listings establish a presence across the United States, Singapore, Japan, the United Kingdom, and Ireland, but do not by themselves establish the full scope of commercial operations in those markets. A named development program in the company’s homepage announcements is WVE-007, described as a GalNAc-siRNA and associated with INHBE. The homepage reports the initiation of the Phase 2a portion of the INLIGHT trial in June 2026 and, in September 2026, the initiation of a Phase 2a combination trial with tirzepatide for obesity. These are company-reported clinical-development milestones and do not demonstrate approval, launch, or efficacy beyond what is stated in the announcements. The leadership page identifies Paul Bolno as president and chief executive officer and lists senior leaders across technology, science, medical affairs, finance, business, strategy, human resources, legal, translational medicine, and chemistry, manufacturing, and controls. The homepage reports the appointment of Monika Vnuk as chief business officer in September 2026. The company’s contact page documents a corporate headquarters in Cambridge; the supplied evidence does not identify a parent or owner, a stock ticker, or a confirmed listing status. Wave’s corporate responsibility page describes company-wide commitments covering environmental, social, and governance initiatives, with particular attention to diversity, equity and inclusion, human capital, and patient and community engagement. It says the Nominating & Corporate Governance Committee provides oversight of corporate sustainability initiatives and strategies. The company homepage lists announcements in August 2026 concerning the expected completion and completion of a redomiciliation to Delaware. These announcements mark a corporate-structure development, but the supplied evidence does not provide further details of the transaction.

• The company announces initiation of the Phase 2a portion of the INLIGHT trial of WVE-007.

• The company announces completion of its redomiciliation to Delaware.

• The company announces Dr. Monika Vnuk’s appointment as Chief Business Officer.

• The company announces initiation of a Phase 2a WVE-007 combination trial with tirzepatide for obesity.

A research-led biotechnology company developing RNA medicines through RNA-targeting modalities, chemistry innovation, and human-genetics insights, with programs intended to address rare and common disorders.

• WVE-007

  A GalNAc-siRNA program associated with INHBE; the company reports clinical development including Phase 2a trial activity.

1. 1Wave Life Scienceswavelifesciences.com
2. 2Corporate Responsibility - Wave Life Scienceswavelifesciences.com
3. 3Contact Us - Wave Life Scienceswavelifesciences.com
4. 4Leadership - Wave Life Scienceswavelifesciences.com
5. 5Wave Life Scienceswikidata.org